| abstract |
SGLT2 inhibitor compounds of the formula are described wherein R1, R2 and R2a are independently hydrogen, OH, OR5, lower alkyl, CF3, OCHF2, OCF3, SR5 'or halogen, or two of R1, R2 and R2a together with the carbon atoms to which they are attached. , may form an annealed five-, six- or seven-membered carbocyclic or heterocyclic ring; R3 and R4 are independently hydrogen, OH, OR5a, OAryl, OCH2Aryl, lower alkyl, cycloalkyl, CF3, -OCHF2, -OCF3l halogen, -CN, -CO2R5b, -CO2H, -COR6b, -CH (OH) R6c, -CH ^ R ^ R * 1, -CONR6R6a, -NHCOR5c, -NHSOgR501, -NHSO2Aryl, Aryl, -SR5e, -SOR5f, -SO2R5g, -SO2Aryl, or a five-, six- or seven-membered heterocyclic ring, or wherein R3 and R 4 together with the carbon atoms to which they are attached form an annealed five-, six- or seven-membered carbocyclic or heterocyclic ring; R5, R53, R5b, R5c, R5d, R5e, R5f, R59, R5h and R5i are independently lower alkyl; R6, R63, R6b, R6c and R6d are independently hydrogen, alkyl, aryl, alkylaryl or cycloalkyl, or R6 and R6a together with the nitrogen atom to which they are attached form an annealed five-, six- or seven-membered heterocyclic ring; A is O, S, NH or (CH 2) n where n is 0-3. There is also provided a method of treating diabetes and related diseases by using an SGLT2 inhibitory amount of the above compound, alone or in combination with another antidiabetic agent or other therapeutic agent. |